Kamada (KMDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA10.42 Million ≈ $27.92K USD) by net assets (ILA265.23 Million ≈ $711.08K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kamada - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kamada (KMDA) financial obligations for a breakdown of total debt and financial obligations.
Kamada Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kamada ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Yuxing Film Tech
SHE:300305
|
0.058x |
|
Aarti Drugs Limited
NSE:AARTIDRUGS
|
0.104x |
|
DB Financial Investment Co Ltd
KO:016610
|
-0.116x |
|
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
|
0.008x |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
N/A |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
0.042x |
|
Thessaloniki Port Authority SA
AT:OLTH
|
0.031x |
|
Sinomach General Machinery Science Technology Co Ltd
SHG:600444
|
0.093x |
Annual Cash Flow Conversion Efficiency for Kamada (2007–2024)
The table below shows the annual cash flow conversion efficiency of Kamada from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see KMDA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA259.46 Million ≈ $695.61K |
ILA47.59 Million ≈ $127.60K |
0.183x | +937.34% |
| 2023-12-31 | ILA244.02 Million ≈ $654.21K |
ILA4.32 Million ≈ $11.57K |
0.018x | -89.11% |
| 2022-12-31 | ILA176.02 Million ≈ $471.90K |
ILA28.59 Million ≈ $76.64K |
0.162x | +425.62% |
| 2021-12-31 | ILA176.82 Million ≈ $474.06K |
ILA-8.82 Million ≈ $-23.64K |
-0.050x | -146.63% |
| 2020-12-31 | ILA178.64 Million ≈ $478.92K |
ILA19.11 Million ≈ $51.22K |
0.107x | -47.51% |
| 2019-12-31 | ILA135.32 Million ≈ $362.79K |
ILA27.57 Million ≈ $73.92K |
0.204x | +117.11% |
| 2018-12-31 | ILA112.38 Million ≈ $301.28K |
ILA10.55 Million ≈ $28.27K |
0.094x | +115.90% |
| 2017-12-31 | ILA89.49 Million ≈ $239.92K |
ILA3.89 Million ≈ $10.43K |
0.043x | +52.93% |
| 2016-12-31 | ILA66.74 Million ≈ $178.94K |
ILA1.90 Million ≈ $5.09K |
0.028x | +114.74% |
| 2015-12-31 | ILA72.51 Million ≈ $194.39K |
ILA-13.98 Million ≈ $-37.48K |
-0.193x | -57.44% |
| 2014-12-31 | ILA80.99 Million ≈ $217.14K |
ILA-9.92 Million ≈ $-26.59K |
-0.122x | -185.86% |
| 2013-12-31 | ILA89.97 Million ≈ $241.21K |
ILA-3.85 Million ≈ $-10.33K |
-0.043x | +85.28% |
| 2012-12-31 | ILA28.39 Million ≈ $76.12K |
ILA-8.26 Million ≈ $-22.15K |
-0.291x | -801.65% |
| 2011-12-31 | ILA22.67 Million ≈ $60.79K |
ILA940.36K ≈ $2.52K |
0.041x | -89.67% |
| 2010-12-31 | ILA26.49 Million ≈ $71.01K |
ILA10.63 Million ≈ $28.50K |
0.401x | +192.43% |
| 2009-12-31 | ILA30.15 Million ≈ $80.83K |
ILA-13.09 Million ≈ $-35.10K |
-0.434x | +56.84% |
| 2008-12-31 | ILA12.64 Million ≈ $33.89K |
ILA-12.72 Million ≈ $-34.11K |
-1.006x | -456.76% |
| 2007-12-31 | ILA69.57 Million ≈ $186.51K |
ILA-12.57 Million ≈ $-33.71K |
-0.181x | -- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more